This web site provides clinical trial data results and other information regarding clinical trials.

Trimaran clinical trial. Virchow JC Kuna P Paggiaro P Papi A Singh D Corre S Zuccaro F Vele A Kots M Georges G Petruzzelli S Canonica GW. National Library of Medicine. Two randomised double-blind 3 parallel group controlled trials TRIMARAN and TRIGGER 4 Authors 5 Prof.

2 Selroos O et al. Single inhaler extrafine triple therapy in uncontrolled asthma. ClinicalTrialsgov is a database of privately and publicly funded clinical studies conducted around the world.

The full design and inclusionexclusion criteria of TRIMARAN and TRIGGER have been previously published Both studies recruited populations aged 1875 years inclusive with a documented history of asthma for at least one year and diagnosed prior to the age of 40 years pre-bronchodilator FEV 1 80 of the predicted normal value and a change in FEV 1 of. Triton was built and delivered by the UK shipbuilder Vosper Thornycroft in August 2000. Johann Christian Virchow MD1 Prof.

Trials of the trimaran hull have been carried out over the past two years with the research vessel Triton. TRIMARAN and TRIGGER manuscript 21 August 2019 Page 1 of 33 1 Title 2 Single inhaler extrafine triple therapy in uncontrolled asthma. Two parallel-group double-blind randomised active-controlled phase 3 trials Triple in Asthma With Uncontrolled Patients on Medium Strength of ICS LABA TRIMARAN and Triple in Asthma High Strength Versus ICSLABA HS and Tiotropium TRIGGER recruited patients from 171 sites across 16 countries TRIMARAN and from 221 sites across 17 countries TRIGGER.

This item is a queen elizabeth ii first. National and regional asthma programmes in Europe. Modern trimarans look futuristic with their sharp hulls design and racing rigs but the first trimarans were built by indigenous Polynesians and other Pacific islanders almost 4000 years ago.

Piotr Kuna 3MD2 Prof. In TRIMARAN patients were randomly assigned 11 to 52 weeks of BDPFFG 100 μg BDP 6 μg FF and 10 μg G or BDPFF 100 μg BDP and 6 μg FF two inhalations twice daily. Two double-blind parallel-group randomised controlled phase 3 trials.